Northern Trust Corp lessened its holdings in shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,066,046 shares of the biotechnology company’s stock after selling 15,057 shares during the quarter. Northern Trust Corp’s holdings in Progenics Pharmaceuticals were worth $4,476,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Prudential Financial Inc. lifted its holdings in Progenics Pharmaceuticals by 11.3% in the third quarter. Prudential Financial Inc. now owns 136,292 shares of the biotechnology company’s stock valued at $855,000 after acquiring an additional 13,790 shares during the period. Bank of New York Mellon Corp lifted its holdings in Progenics Pharmaceuticals by 9.2% in the third quarter. Bank of New York Mellon Corp now owns 1,160,542 shares of the biotechnology company’s stock valued at $7,277,000 after acquiring an additional 97,561 shares during the period. BlackRock Inc. lifted its holdings in Progenics Pharmaceuticals by 16.7% in the third quarter. BlackRock Inc. now owns 13,293,243 shares of the biotechnology company’s stock valued at $83,349,000 after acquiring an additional 1,902,006 shares during the period. Credit Suisse AG lifted its holdings in Progenics Pharmaceuticals by 22.2% in the third quarter. Credit Suisse AG now owns 78,520 shares of the biotechnology company’s stock valued at $492,000 after acquiring an additional 14,253 shares during the period. Finally, Allianz Asset Management GmbH lifted its holdings in Progenics Pharmaceuticals by 9.3% in the third quarter. Allianz Asset Management GmbH now owns 254,619 shares of the biotechnology company’s stock valued at $1,596,000 after acquiring an additional 21,635 shares during the period. 87.59% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have commented on PGNX. Zacks Investment Research raised Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Thursday, February 21st. BidaskClub raised Progenics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.35.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.14). The firm had revenue of $3.24 million for the quarter, compared to analyst estimates of $10.99 million. Progenics Pharmaceuticals had a negative return on equity of 59.85% and a negative net margin of 433.09%. On average, analysts expect that Progenics Pharmaceuticals, Inc. will post -0.62 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/22/progenics-pharmaceuticals-inc-pgnx-holdings-trimmed-by-northern-trust-corp.html.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Further Reading: Understanding Market Liquidity
Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.